- About this Journal ·
- Abstracting and Indexing ·
- Advance Access ·
- Aims and Scope ·
- Annual Issues ·
- Article Processing Charges ·
- Articles in Press ·
- Author Guidelines ·
- Bibliographic Information ·
- Citations to this Journal ·
- Contact Information ·
- Editorial Board ·
- Editorial Workflow ·
- Free eTOC Alerts ·
- Publication Ethics ·
- Reviewers Acknowledgment ·
- Submit a Manuscript ·
- Subscription Information ·
- Table of Contents
Clinical and Developmental Immunology
Volume 2011 (2011), Article ID 549281, 11 pages
Novel Prophylactic Vaccine Using a Prime-Boost Method and Hemagglutinating Virus of Japan-Envelope against Tuberculosis
1Clinical Research Center, National Hospital Organization, Kinki-Chuo Chest Medical Center, 1180 Nagasone, Kitaku, Sakai, Osaka 591-8555, Japan
2Ikeda Laboratory, GenomIdea Inc.,1-8-31 Midorigaoka, Ikeda, Osaka 530-0043, Japan
3Division of Gene Therapy Science, Graduate School of Medicine, Osaka University, 2-2 Yamadaoka, Suita, Osaka 565-0871, Japan
4Department of Medical Zoology, Jichi Medical School, 3311-1 Yakushiji, Minamikawachi-machi, Tochigi 329-0498, Japan
5System Health Science Center, College of Medicine, Texas A&M University, College Station, TX 77843-1114, USA
Received 8 September 2010; Revised 6 January 2011; Accepted 16 January 2011
Academic Editor: Nicholas West
Copyright © 2011 Masaji Okada et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
- J. L. Flynn and J. Chan, “Immunology of tuberculosis,” Annual Review of Immunology, vol. 19, pp. 93–129, 2001.
- J. Hess, U. Schaible, B. Raupach, and S. H. E. Kaufmann, “Exploiting the immune system: toward new vaccines against intracellular bacteria,” Advances in Immunology, vol. 75, pp. 1–88, 2000.
- A. Geluk, K. E. Van Meijgaarden, K. L. M. C. Franken et al., “Identification of major epitopes of Mycobacterium tuberculosis AG85B that are recognized by HLA-A*0201-restricted CD8+ T cells in HLA-transgenic mice and humans,” Journal of Immunology, vol. 165, no. 11, pp. 6463–6471, 2000.
- A. Lalvani, R. Brookes, R. J. Wilkinson et al., “Human cytolytic and interferon γ-secreting CD8+ T lymphocytes specific for Mycobacterium tuberculosis,” Proceedings of the National Academy of Sciences of the United States of America, vol. 95, no. 1, pp. 270–275, 1998.
- P. Wong and E. G. Pamer, “CD8 T cell responses to infectious pathogens,” Annual Review of Immunology, vol. 21, pp. 29–70, 2003.
- H. McShane, S. Behboudi, N. Goonetilleke, R. Brookes, and A. V. S. Hill, “Protective immunity against Mycobacterium tuberculosis induced by dendritic cells pulsed with both CD8(+)- and CD4(+)-T-cell epitopes from antigen 85A,” Infection and Immunity, vol. 70, no. 3, pp. 1623–1626, 2002.
- I. K. Srivastava and M. A. Liu, “Gene vaccines,” Annals of Internal Medicine, vol. 138, no. 7, pp. 550–I48, 2003.
- M. Okada and T. Kishimoto, “The potential application and limitation of cytokine/growth factor manipulation in cancer therapy,” in Cell proliferation in Cancer: Regulatory Mechanisms of Neoplastic Cell Growth, L. Pusztai, C. Lewis, and E. Yap, Eds., pp. 218–244, Oxford University Press, New York, NY, USA, 1996.
- M. J. Roy, M. S. Wu, L. J. Barr et al., “Induction of antigen-specific CD8+ T cells, T helper cells, and protective levels of antibody in humans by particle-mediated administration of a hepatitis B virus DNA vaccine,” Vaccine, vol. 19, no. 7-8, pp. 764–778, 2000.
- T. P. Le, K. M. Coonan, R. C. Hedstrom et al., “Safety, tolerability and humoral immune responses after intramuscular administration of a malaria DNA vaccine to healthy adult volunteers,” Vaccine, vol. 18, no. 18, pp. 1893–1901, 2000.
- A. C. Moore and A. V. S. Hill, “Progress in DNA-based heterologous prime-boost immunization strategies for malaria,” Immunological Reviews, vol. 199, pp. 126–143, 2004.
- S. Yoshida, S. I. Kashiwamura, Y. Hosoya et al., “Direct immunization of malaria DNA vaccine into the liver by gene gun protects against lethal challenge of Plasmodium berghei sporozoite,” Biochemical and Biophysical Research Communications, vol. 271, no. 1, pp. 107–115, 2000.
- J. D. Boyer, M. A. Chattergoon, K. E. Ugen et al., “Enhancement of cellular immune response in HIV-1 seropositive individuals: a DNA-based trial,” Clinical Immunology, vol. 90, no. 1, pp. 100–107, 1999.
- K. Huygen, “DNA vaccines: application to tuberculosis,” International Journal of Tuberculosis and Lung Disease, vol. 2, no. 12, pp. 971–978, 1998.
- D. B. Lowrie, “DNA vaccines against tuberculosis,” Current Opinion in Molecular Therapeutics, vol. 1, no. 1, pp. 30–33, 1999.
- I. M. Orme, “The search for new vaccines against tuberculosis,” Journal of Leukocyte Biology, vol. 70, no. 1, pp. 1–10, 2001.
- T. M. Doherty and P. Andersen, “Tuberculosis vaccine development,” Current Opinion in Pulmonary Medicine, vol. 8, no. 3, pp. 183–187, 2002.
- D. M. McMurray, “Guinea pig model of tuberculosis,” in Tuberculosis: Pathogenesis, Protection, and Control, pp. 113–134, ASM Press, Washington, DC, USA, 1994.
- S. Yoshida, T. Tanaka, Y. Kita et al., “DNA vaccine using hemagglutinating virus of Japan-liposome encapsulating combination encoding mycobacterial heat shock protein 65 and interleukin-12 confers protection against Mycobacterium tuberculosis by T cell activation,” Vaccine, vol. 24, no. 8, pp. 1191–1204, 2006.
- Y. Kita, T. Tanaka, S. Yoshida et al., “Novel recombinant BCG and DNA-vaccination against tuberculosis in a cynomolgus monkey model,” Vaccine, vol. 23, no. 17-18, pp. 2132–2135, 2005.
- M. Okada, Y. Kita, T. Nakajima et al., “Evaluation of a novel vaccine (HVJ-liposome/HSP65 DNA + IL-12 DNA) against tuberculosis using the cynomolgus monkey model of TB,” Vaccine, vol. 25, no. 16, pp. 2990–2993, 2007.
- M. Okada, Y. Kita, T. Nakajima et al., “Novel prophylactic and therapeutic vaccine against tuberculosis,” Vaccine, vol. 27, no. 25-26, pp. 3267–3270, 2009.
- Y. Saeki, N. Matsumoto, Y. Nakano, M. Mori, K. Awai, and Y. Kaneda, “Development and characterization of cationic liposomes conjugated with HVJ (Sendai virus): reciprocal effect of cationic lipid for in vitro and in vivo gene transfer,” Human Gene Therapy, vol. 8, no. 17, pp. 2133–2141, 1997.
- K. Miki, T. Nagata, T. Tanaka et al., “Induction of protective cellular immunity against Mycobacterium tuberculosis by recombinant attenuated self-destructing Listeria monocytogenes strains harboring eukaryotic expression plasmids for antigen 85 complex and MPB/MPT51,” Infection and Immunity, vol. 72, no. 4, pp. 2014–2021, 2004.
- C. C. Dascher, K. Hiromatsu, X. Xiong et al., “Immunization with a mycobacterial lipid vaccine improves pulmonary pathology in the guinea pig model of tuberculosis,” International Immunology, vol. 15, no. 8, pp. 915–925, 2003.
- I. Sugawara, T. Udagawa, S. C. Hua et al., “Pulmonary granulomas of guinea pigs induced by inhalation exposure of heat-treated BCG Pasteur, purified trehalose dimycolate and methyl ketomycolate,” Journal of Medical Microbiology, vol. 51, no. 2, pp. 131–137, 2002.
- Y. Kita, M. Okada, T. Nakajima, et al., “Development of therapeutic and prophylactic vaccine against Tuberculosis using monkey and transgenic mice models,” Human Vaccines, vol. 7, pp. 108–114, 2011.
- H. McShane, A. A. Pathan, C. R. Sander et al., “Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG-primed and naturally acquired antimycobacterial immunity in humans,” Nature Medicine, vol. 10, no. 11, pp. 1240–1244, 2004.
- H. A. Fletcher, A. A. Pathan, T. K. Berthoud et al., “Boosting BCG vaccination with MVA85A down-regulates the immunoregulatory cytokine TGF-β1,” Vaccine, vol. 26, no. 41, pp. 5269–5275, 2008.
- M. Okada and Y. Kita, “Tuberculosis vaccine development: the development of novel (preclinical) DNA vaccine,” Human Vaccines, vol. 6, no. 4, pp. 297–308, 2010.
- S. H. Kaufmann, G. Hussey, and P. H. Lambert, “New vaccines for tuberculosis,” The Lancet, vol. 375, no. 9731, pp. 2110–2119, 2010.
- D. B. Lowrie, R. E. Tascon, V. L. D. Bonato et al., “Therapy of tuberculosis in mice by DNA vaccination,” Nature, vol. 400, no. 6741, pp. 269–271, 1999.
- D. F. Hoft, “Tuberculosis vaccine development: goals, immunological design, and evaluation,” The Lancet, vol. 372, no. 9633, pp. 164–175, 2008.
- U. D. Gupta, V. M. Katoch, and D. N. McMurray, “Current status of TB vaccines,” Vaccine, vol. 25, no. 19, pp. 3742–3751, 2007.
- F. Tanaka, M. Abe, T. Akiyoshi et al., “The anti-human tumor effect and generation of human cytotoxic T cells in SCID mice given human peripheral blood lymphocytes by the in vivo transfer of the interleukin-6 gene using adenovirus vector,” Cancer Research, vol. 57, no. 7, pp. 1335–1343, 1997.
- H. McShane, A. A. Pathan, and C. R. Sander, “Recombinant modified vaccinia virus Ankara expressing antigen 85A boosters BCG-primed and naturally acquired antimycobacterial immunity in humans,” Nature Medicine, vol. 10, pp. 1240–1244, 2008.
- M. Tanaka, Y. Kaneda, S. Fujii et al., “Induction of a systemic immune response by a polyvalent melanoma-associated antigen DNA vaccine for prevention and treatment of malignant melanoma,” Molecular Therapy, vol. 5, no. 3, pp. 291–299, 2002.
- S. Takeda, K. Shiosaki, Y. Kaneda et al., “Hemagglutinating virus of Japan protein is efficient for induction of CD4(+) T-cell response by a hepatitis B core particle-based HIV vaccine,” Clinical Immunology, vol. 112, no. 1, pp. 92–105, 2004.
- G. Sakaue, T. Hiroi, Y. Nakagawa et al., “HIV mucosal vaccine: nasal immunization with gp160-encapsulated hemagglutinating virus of Japan-liposome induces antigen-specific CTLs and neutralizing antibody responses,” Journal of Immunology, vol. 170, no. 1, pp. 495–502, 2003.
- Y. Kaneda, T. Nakajima, T. Nishikawa et al., “Hemagglutinating virus of Japan (HVJ) envelope vector as a versatile gene delivery system,” Molecular Therapy, vol. 6, no. 2, pp. 219–226, 2002.
- Y. Kaneda, “New vector innovation for drug delivery: development of fusigenic non-viral particles,” Current Drug Targets, vol. 4, no. 8, pp. 599–602, 2003.
- Y. Kaneda, S. Yamamoto, and T. Nakajima, “Development of HVJ Envelope Vector and Its Application to Gene Therapy,” Advances in Genetics, vol. 53, pp. 307–332, 2005.
- M. Ito, S. Yamamoto, K. Nimura, K. Hiraoka, K. Tamai, and Y. Kaneda, “Rad51 siRNA delivered by HVJ envelope vector enhances the anti-cancer effect of cisplatin,” Journal of Gene Medicine, vol. 7, no. 8, pp. 1044–1052, 2005.
- H. Mima, S. Yamamoto, M. Ito et al., “Targeted chemotherapy against intraperitoneally disseminated colon carcinoma using a cationized gelatin-conjugated HVJ envelope vector,” Molecular Cancer Therapeutics, vol. 5, no. 4, pp. 1021–1028, 2006.
- A. M. Cooper, J. Magram, J. Ferrante, and I. M. Orme, “Interleukin 12 (IL-12) is crucial to the development of protective immunity in mice intravenously infected with Mycobacterium tuberculosis,” Journal of Experimental Medicine, vol. 186, no. 1, pp. 39–45, 1997.
- K. M. Baek, S. Y. Ko, M. Lee et al., “Comparative analysis of effects of cytokine gene adjuvants on DNA vaccination against Mycobacterium tuberculosis heat shock protein 65,” Vaccine, vol. 21, no. 25-26, pp. 3684–3689, 2003.
- E. Martin, A. T. Kamath, H. Briscoe, and W. J. Britton, “The combination of plasmid interleukin-12 with a single DNA vaccine is more effective than Mycobacterium bovis (bacille Calmette-Guèrin) in protecting against systemic Mycobacterim avium infection,” Immunology, vol. 109, no. 2, pp. 308–314, 2003.